Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 16/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22221342 | 1.00 | PDE2A (0.67) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL20811529 | 1.00 | PDE2A (0.67) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL29685925 | 0.85 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL30557838 | 0.85 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL4233776 | 0.85 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL4550763 | 0.85 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL14120778 | 0.85 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL31136623 | 0.84 | PDE2A (0.54) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| Hydrochloric Acid SCHEMBL2715888 | 0.84 | PDE2A (0.64) | PDE2AHTR2AHTR2CHTR2BIDO1 | |
| Hydrochloric Acid SCHEMBL31136371 | 0.82 | PDE2A (0.53) | PDE2AHTR2AHTR2CHTR2BIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | AMGEN INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | PDE2A 212/4885HTR2A 3357/4885HTR2C 4327/4885 |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | PDE2A 212/4885HTR2A 3357/4885HTR2C 4327/4885 |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | TNNI3, TNNT2, TNNC1 | PDE2A 971/4885HTR2A 2001/4885HTR2C 3674/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | PDE2A 212/4885HTR2A 3357/4885HTR2C 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.